Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Symptoms and General Pathology

Blood and Lymph Conditions

Immune System Diseases

Nervous System Diseases

Rare Diseases

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Neoplasm Metastasis

Lymphoma

Carcinoma

Neoplasms, Second Primary

Brain Neoplasms

Meningeal Carcinomatosis

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

Neoplastic Processes

Central Nervous System Neoplasms

Nervous System Neoplasms

Brain Diseases

Central Nervous System Diseases

Meningeal Neoplasms

Lymphosarcoma

Lorlatinib

This study was a retrospective observational study. The study included patients with non-small cell lung cancer with ALK-fusion brain metastases or meningeal metastases who received first-line and late-line treatment with the third-generation ALK TKI lorlatinib between June 2022 and June 2023.

Data were collected from the electronic medical records database and hospital information system of many hospitals in Sichuan Province. Clinical pathology features including gender, age, ALK mutation status at diagnosis, and clinical stage at diagnosis were collected from the medical records. The physical condition assessed by ECOG-PS before the administration of lorlatinib was recorded. Information on anti-tumor therapy was obtained from the records, including dose and time of ALK-TKI therapy and tumor response, number of prior systemic therapy lines, drug regimen, efficacy, and whether local therapy such as radiotherapy and surgery had been received. In this study, the sample size is not limited, and information is collected according to the maximum number of patients. The study period was from 01 July 2023 to 30 June 2024.

A Retrospective Study of the Efficacy and Safety of Lolatinib in ALK+ NSCLC Patients With Brain or Meningeal Metastasis

A Retrospective Study of the Efficacy and Safety of Lolatinib in Anaplastic Lymphoma Kinase (ALK) - Positive Non-Small Cell Lung Cancer (NSCLC) Patients With Brain or Meningeal Metastasis

the Sum of percentage of participants with CR and PR as assessed by RECIST v1.1 or RANO-BM criteria every 8-12 weeks.

Intracranial and systemic PFS as assessed by the investigators using RECIST V1.1 or RANO-BM Separately.

Overall survival for first-line and late-line of lorlatinib medication

Number and percentage of participants with treatment-related AEs as assessed by CTCAE v5.0, and the duration of AEs on every grade

Sichuan Cancer Hospital and Research Institute

Principal Investigator

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
A Retrospective Study of the Efficacy and Safety of Lolatinib in ALK+ NSCLC Patients With Brain or Meningeal Metastasis	NCT06410040	ALK-positive No... Brain Metastase... Meningeal Metas...	Lorlatinib	18 Years -	Sichuan Cancer Hospital and Research Institute
A Retrospective Study of the Efficacy and Safety of Lolatinib in ALK+ NSCLC Patients With Brain or Meningeal Metastasis	NCT06410040	ALK-positive No... Brain Metastase... Meningeal Metas...	Lorlatinib	18 Years -	Sichuan Cancer Hospital and Research Institute
A Retrospective Study of the Efficacy and Safety of Lolatinib in ALK+ NSCLC Patients With Brain or Meningeal Metastasis	NCT06410040	ALK-positive No... Brain Metastase... Meningeal Metas...	Lorlatinib	18 Years -	Sichuan Cancer Hospital and Research Institute

Spots Global Cancer Trial Database for meningeal metastasis